Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Brennan Carrithers & Rif S El-Mallakh. (2020) Transdermal Asenapine in Schizophrenia: A Systematic Review. Patient Preference and Adherence 14, pages 1541-1551.
Read now
Read now
Mitali Patel, Veenu Mundada & Krutika Sawant. (2019) Enhanced intestinal absorption of asenapine maleate by fabricating solid lipid nanoparticles using TPGS: elucidation of transport mechanism, permeability across Caco-2 cell line and in vivo pharmacokinetic studies. Artificial Cells, Nanomedicine, and Biotechnology 47:1, pages 144-153.
Read now
Read now
Peter Dogterom, Robert Riesenberg, Rik de Greef, Justin Dennie, Martin Johnson, Venkatesh Pilla Reddy, André MM Miltenburg, Robert L Findling, Abhijeet Jakate, Timothy J Carrothers & Matthew D Troyer. (2018) Asenapine pharmacokinetics and tolerability in a pediatric population. Drug Design, Development and Therapy 12, pages 2677-2693.
Read now
Read now
Bernardo Dell’Osso, Laura Cremaschi, Maria Carlotta Palazzo, Gregorio Spagnolin, Alma Cattaneo, Benedetta Grancini, Matteo Maggi & Alfredo Carlo Altamura. (2014) Use of asenapine as add-on therapy in the treatment of bipolar disorder: a comprehensive review and case series. Expert Opinion on Drug Safety 13:9, pages 1199-1208.
Read now
Read now
Leslie Citrome. (2014)
Asenapine review, part II: clinical efficacy, safety and tolerability. Expert Opinion on Drug Safety 13:6, pages 803-830.
Read now
Read now
Maurizio Pompili, Paola Venturini, Marco Innamorati, Gianluca Serafini, Ludovica Telesforo, David Lester, Roberto Tatarelli & Paolo Girardi. (2011) The role of asenapine in the treatment of manic or mixed states associated with bipolar I disorder. Neuropsychiatric Disease and Treatment 7, pages 259-265.
Read now
Read now
Maurizio Pompili, Gianluca Serafini, Marco Innamorati, Elisa Ambrosi, Ludovica Telesforo, Paola Venturini, Gloria Giordano, Michele Battuello, David Lester & Paolo Girardi. (2011) Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option?. Expert Review of Neurotherapeutics 11:7, pages 989-1006.
Read now
Read now
Articles from other publishers (15)
Wisam Al Jumaili & Shailesh Jain. (2022) Role of asenapine as an augmenter for treatment-resistant schizophrenia. Psychiatry Research Case Reports 1:2, pages 100019.
Crossref
Crossref
Nagara Takao, Toshiya Murai & Hironobu Fujiwara. (2021) Treatment-resistant schizophrenia characterised by dopamine supersensitivity psychosis and efficacy of asenapine. BMJ Case Reports 14:4, pages e242495.
Crossref
Crossref
Eman Salah, Mahmoud M. Abouelfetouh, Yuanhu Pan, Dongmei Chen & Shuyu Xie. (2020) Solid lipid nanoparticles for enhanced oral absorption: A review. Colloids and Surfaces B: Biointerfaces 196, pages 111305.
Crossref
Crossref
Kevin Ita. 2020. Transdermal Drug Delivery. Transdermal Drug Delivery
37
62
.
Mitali H. Patel, Veenu P. Mundada & Krutika K. Sawant. (2019) Novel Drug Delivery Approach via Self-Microemulsifying Drug Delivery System for Enhancing Oral Bioavailability of Asenapine Maleate: Optimization, Characterization, Cell Uptake, and In Vivo Pharmacokinetic Studies. AAPS PharmSciTech 20:2.
Crossref
Crossref
Dhrubajyoti BhuyanSoumitra GhoshArnab BhattacharyaSamir Kumar Praharaj. (2016) Asenapine-Induced Acute Dystonia in an Adolescent Male. Journal of Child and Adolescent Psychopharmacology 26:10, pages 955-956.
Crossref
Crossref
Toshihiko Kinoshita, Ya-Mei Bai, Jong-Hoon Kim, Mutsuo Miyake & Nobuyuki Oshima. (2016) Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology 233:14, pages 2663-2674.
Crossref
Crossref
Paul D. Shilling & David Feifel. (2016) Potential of Oxytocin in the Treatment of Schizophrenia. CNS Drugs 30:3, pages 193-208.
Crossref
Crossref
Abigail Perez Rodriguez, Kazuhiro Tajima-Pozo, Adrian Lewczuk & Francisco Montañes-Rada. (2015) Atypical antipsychotics and metabolic syndrome. Cardiovascular Endocrinology 4:4, pages 132-137.
Crossref
Crossref
Ravi Philip Rajkumar. (2014) Supersensitivity Psychosis and Its Response to Asenapine in a Patient with Delusional Disorder. Case Reports in Psychiatry 2014, pages 1-3.
Crossref
Crossref
Melvin George, Radhika Amrutheshwar, Ravi Philip Rajkumar, Shivanand Kattimani & Steven Aibor Dkhar. (2013) Newer antipsychotics and upcoming molecules for schizophrenia. European Journal of Clinical Pharmacology 69:8, pages 1497-1509.
Crossref
Crossref
David P. Rotella. 2012. Drug Discovery for Psychiatric Disorders. Drug Discovery for Psychiatric Disorders
35
55
.
Jens-Uwe Peters, Jérôme Hert, Caterina Bissantz, Alexander Hillebrecht, Grégori Gerebtzoff, Stefanie Bendels, Fabien Tillier, Jacques Migeon, Holger Fischer, Wolfgang Guba & Manfred Kansy. (2012) Can we discover pharmacological promiscuity early in the drug discovery process?. Drug Discovery Today 17:7-8, pages 325-335.
Crossref
Crossref
Jared W Young, Brook L Henry & Mark A Geyer. (2011) Predictive animal models of mania: hits, misses and future directions. British Journal of Pharmacology 164:4, pages 1263-1284.
Crossref
Crossref
HY Meltzer & BW Massey. (2011) The role of serotonin receptors in the action of atypical antipsychotic drugs. Current Opinion in Pharmacology 11:1, pages 59-67.
Crossref
Crossref